Dasatinib for the treatment of acute lymphoblastic leukaemia
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 386
Referral date 01 June 2008
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 December 2008 Please note that this topic has been removed from the technology appraisals work programme.

For further information on our processes and methods, please see our CHTE processes and methods manual